Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Common Equity (2018 - 2022)

NovaBridge Biosciences (NBP) has disclosed Common Equity for 5 consecutive years, with $409.1 million as the latest value for Q4 2022.

  • Quarterly Common Equity fell 42.63% to $409.1 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $409.1 million through Dec 2022, down 42.63% year-over-year, with the annual reading at $417.8 million for FY2022, 41.58% down from the prior year.
  • Common Equity for Q4 2022 was $409.1 million at NovaBridge Biosciences, down from $713.2 million in the prior quarter.
  • The five-year high for Common Equity was $849.1 million in Q4 2020, with the low at -$288.7 million in Q4 2019.
  • Average Common Equity over 5 years is $308.9 million, with a median of $409.1 million recorded in 2022.
  • The sharpest move saw Common Equity tumbled 108.98% in 2019, then skyrocketed 394.13% in 2020.
  • Over 5 years, Common Equity stood at -$138.1 million in 2018, then crashed by 108.98% to -$288.7 million in 2019, then skyrocketed by 394.13% to $849.1 million in 2020, then decreased by 16.01% to $713.2 million in 2021, then tumbled by 42.63% to $409.1 million in 2022.
  • According to Business Quant data, Common Equity over the past three periods came in at $409.1 million, $713.2 million, and $849.1 million for Q4 2022, Q4 2021, and Q4 2020 respectively.